Pharmacotherapy of substance dependence and withdrawal syndromes;Pharmakotherapie von abhängigkeitsund entzugssyndromen

Therapeutische Umschau

Volumn 66, Issue 6, 2009, Pages 449-457

  Walter, Marc ^a   Wiesbeck, Gerhard A ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; AMANTADINE; AMANTADINE SULFATE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; BUPRENORPHINE; CARBAMAZEPINE; CHLORPROTHIXENE; CLOMETHIAZOLE; CLONIDINE; DIAZEPAM; DISULFIRAM; HALOPERIDOL; HYPNOTIC AGENT; IMIPRAMINE; LISURID; LORAZEPAM; METHADONE; METHYLPHENIDATE; METOCLOPRAMIDE; NALTREXIN; NALTREXONE; NEMEXIN; NEUROLEPTIC AGENT; OXAZEPAM; RIMONABANT; THIAMINE; TIAGABINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLPIDEM; ZOLPIDEM TARTRATE; ZOPICLONE; ALCOHOL; PSYCHOTROPIC AGENT; STREET DRUG;

ALCOHOL WITHDRAWAL; ALCOHOLISM; ATTENTION DEFICIT DISORDER; CANNABIS ADDICTION; COCAINE DEPENDENCE; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG INTOXICATION; DRUG WITHDRAWAL; HARM REDUCTION; HUMAN; MENTAL DISEASE; NICOTINE REPLACEMENT THERAPY; OPIATE ADDICTION; PSYCHOSOCIAL CARE; RECURRENT DISEASE; RELAPSE; REVIEW; SMOKING CESSATION; SUBSTANCE ABUSE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME; ADDICTION; CLASSIFICATION;

ALCOHOLISM; ETHANOL; HUMANS; PSYCHOTROPIC DRUGS; RECURRENCE; STREET DRUGS; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 66949111914     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.66.6.449     Document Type: Review

References (20)

1. Saß H, Wittchen HU, Zaudig M, Houben I. Diagnostisches und Statistisches Manual Psychischer Störungen - Textrevision - DSM-IV- TR. Göttingen: Hogrefe, 2003.
2. Dilling H, Mombour W, Schmidt MH. Internationale Klassifikation psychischer Störungen: ICD-10, Kapitel V (F). Klinisch-diagnostische Leitlinien, Weltgesundheitsorganisation. Bern: Huber, 1991.
3. Walter M, Gunderson JG, Zanarini MC et al. New onsets of substance use disorders in borderline personality disorder over seven years of follow-ups: Findings from the Collaborative Longitudinal Personality Disorders Study. Addiction 2009; 104: 97-103.
4. Schmidt LG, Gastpar M, Falkai P, Gaebel W, Hrsg. Evidenzbasierte Suchtmedizin. Behandlungsleitlinie Substanzbezogene Störungen. Köln: Deutscher Ärzteverlag, 2006.
5. Schweizerische Gesellschaft für Suchtmedizin (SSAM). Medizinische Empfehlungen für substitutionsgestützte Behandlungen (SGB) bei Opioidabhängigkeit. Bern, 2006.
6. McBride O, Teesson M, Hasin D et al. Further evidence of differences in substance use and dependence between Australia and the United States. Drug Alcohol Depend 2008.
7. Kessler RC, Berglund P, Demler O et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602. (Pubitemid 40973434)
8. Wiesbeck GA, Schuckit MA, Kalmijn JA et al. An evaluation of the history of a marijuana withdrawal syndrome in a large population. Addiction 1996; 91: 1469-1478. (Pubitemid 26362775)
9. Benkert O, Hippius H. Kompendium der psychiatrischen Pharmakotherapie. 6. Auflage. Berlin: Springer, 2007.
10. Soyka M, Kranzler HR, Berglund M et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the biological treatment of substance use and related disorders, part 1: Alcoholism. World J Biol Psychiatry 2008; 9: 6-23. (Pubitemid 351250516)
11. Kranzler HR, van Krik J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001; 25: 1335-1341. (Pubitemid 32868343)
12. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: A controlled study. Alcohol Clin Exp Res 1998; 22: 573-579. (Pubitemid 28242460)
13. Kiefer F, Jahn H, Tarnaske T et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60: 92-99. (Pubitemid 36070869)
14. Wiesbeck GA, Dürsteler-MacFarland KM. Neue Entwicklungen in der Pharmakotherapie der Kokainabhängigkeit. Nervenarzt 2006; 77: 1064-1070. (Pubitemid 44526795)
15. Kampman KM, Pettinati H, Lynch KG et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004; 75: 233-240. (Pubitemid 38993293)
16. Gonzales G, Sevarino K, Sofuoglu M et al. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction 2003; 98: 1625-1632. (Pubitemid 37373861)
17. Carroll KM, Fenton LR, Ball SA et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-depend ent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 2004; 61: 264-272. (Pubitemid 38295828)
18. Dürsteler-MacFarland KM, Stohler R, Moldovanyi A et al. Complaints of heroin-maintained patients: A survey of symptoms ascribed to diacetylmorphine. Drug Alcohol Depend 2006; 81: 231-239. (Pubitemid 43152449)
19. Jorenby DE, Leischow SJ, Nides MA et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685-689. (Pubitemid 29110752)
20. Hays JT, Ebbert JO. Varenicline for tobacco dependence. N Engl J Med 2008; 359: 2018-2024.